Evidence map›Paper›PMID 42251617›Full record

ReviewDiscover nano2026

Stimuli-responsive nanogels as intelligent nanocarriers for tumor microenvironment-triggered anticancer drug delivery.

Ankita Wal, Sarad Pawar Naik Bukke, Nithin Vidiyala, Shahid Jamil, Krishana Kumar Sharma, Abida Khan, Abhijit Dutta, Pavani Sunkishala, Amin Gasmi

Abstract readReview
In one paragraph

Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ankita WalPranveer Singh Institute of Technology (PSIT), National Highway, NH-19, Kanpur, Uttar Pradesh, 209305, India.
Sarad Pawar Naik BukkeDepartment of Pharmaceutics and Pharmaceutical Technology, Kampala International University, Western Campus, P.O. Box 71, Ishaka-Bushenyi, Uganda. drsaradpawar@kiu.ac.ug.ORCID http://orcid.org/0000-0002-5693-2953
Nithin VidiyalaDepartment of Formulation Development, Cerevel Therapeutics, 222 Jacob St, Cambridge, MA, 02141, USA.
Shahid JamilDepartment of Pharmacy, College of Pharmacy, Knowledge University, Erbil, Kurdistan Region, 446015, Iraq.
Krishana Kumar SharmaDepartment of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India.
Abida KhanCenter for Health Research, Northern Border University, Arar, Saudi Arabia.
Abhijit DuttaRoyal School of Medical and Allied Sciences, The Assam Royal Global University, Guwahati, Assam, India.
Pavani SunkishalaDepartment of Validation, PCI Pharma Services, 23 Commerce Drive, Bedford, NH, 03110, USA.
Amin GasmiSociété Francophone Nutrition Clinique et Metabolism, Paris, IIe-de-France, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stimuli-responsive nanogels have been utilized as perfect nanocarriers for anticancer drug delivery because of their on-demand, controlled, and site-specific drug-releasing chemistry. These HNP are cross-linked hydrophilic polymer nanoparticles with a high-water content, biocompatibility, and adjustable reactivity to chemical or physical stimuli (such as pH, temperature, and redox potential, which are among the most extensively studied triggers in cancer-targeted nanogel systems). Because of their structural flexibility, these nanocarriers can react intelligently and passively to the tumor microenvironment's high glutathione content, acid pH, and overexpressed enzymes, ensuring increased intracellular release and reduced systemic toxicity. Cross-linking strategies, top-down and bottom-up production processes, and core characterization methods concerning size, charge, morphology, and release kinetics are the main topics of this article. Anticancer medications like doxorubicin, paclitaxel, camptothecin, and docetaxel have been shown to be well accommodated in a variety of nanogels, including pH-responsive, thermo-responsive, redox-responsive, magnetic-based, and multi-responsive ones for increased bioavailability and anti-tumor activity. In addition, receptor-mediated endocytosis mediated by targeting ligands such as folic acid, hyaluronic acid, aptamers and monoclonal antibodies improves the cellular uptake and uptake in tumor of drug-loaded nanogels. Collectively, intelligence-triggered nanogels stated above possess outstanding benefits in combination therapy, controlled drug release, and theranostic application and so illustrate these as state-of-the-art intelligent delivery systems for tumor treatment. Future goals include optimizing biocompatibility, removing tumor penetration obstacles using techniques including surface charge modification, PEGylation, and enzyme-sensitive cross-linkers, and guaranteeing scalability and therapeutically transferable formulations.

Indexed as

Anticancer drug delivery magnetic nanogelsEndogenous stimulipH-responsiveRedox-responsiveSmart hydrogel nanoparticlesStimuli-responsive nanogelsTumor microenvironment

Identifiers

PMID42251617
PMCPMC13243166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.